Development and delivery of RNA therapeutics
The Goldberg Lab seeks to leverage the tools of drug delivery to manipulate the cell-extrinsic aspects of cancer in the tumor microenvironment. In particular, Dr. Goldberg recently joined our faculty to apply RNAi-based therapeutics to cancer immunotherapy. He has particular expertise in the development and delivery of cancer-specific siRNAs that target synthetic lethality and aberrant alternative splicing programs. Dr. Goldberg is credited with delivering the first single-agent synthetic lethal siRNA therapeutic in vivo – siRNA targeting Parp1 – for treatment of BRCA1-deficient ovarian cancer; more recently, he demonstrated that siRNA sequences specific to the cancer-expressed M2 isoform of pyruvate kinase induce apoptosis and tumor regression – independent of the cancer type or underlying genetic lesions – without affecting the viability of normal cells.
The focus of current studies includes targeting siRNA delivery to immune cells in vivo. Dr. Goldberg’s diverse training in chemistry, materials science, biotechnology, and molecular biology is combined with cutting-edge mRNA- and siRNA-based as well as nanoparticle-based therapeutic strategies, promising to yield innovative approaches to cancer immunotherapy.
Dana-Farber Cancer Institute450 Brookline Avenue
Smith Research Laboratories, Room 770C
Boston, MA 02215
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: